PROMIS NEUROSCIENCES INC COMMON SHARES (OTCMKTS:ARFXF) had an increase of 11.33% in short interest. ARFXF’s SI was 504,100 shares in July as released by FINRA. Its up 11.33% from 452,800 shares previously. With 203,200 avg volume, 3 days are for PROMIS NEUROSCIENCES INC COMMON SHARES (OTCMKTS:ARFXF)’s short sellers to cover ARFXF’s short positions. The stock decreased 5.66% or $0.0096 during the last trading session, reaching $0.16. About 177,798 shares traded or 57.01% up from the average. ProMIS Neurosciences, Inc. (OTCMKTS:ARFXF) has 0.00% since July 13, 2018 and is . It has underperformed by 4.43% the S&P500.
Farallon Capital Management Llc increased Chemocentryx Inc (CCXI) stake by 3.45% reported in 2019Q1 SEC filing. Farallon Capital Management Llc acquired 50,000 shares as Chemocentryx Inc (CCXI)’s stock rose 15.42%. The Farallon Capital Management Llc holds 1.50 million shares with $20.84 million value, up from 1.45M last quarter. Chemocentryx Inc now has $493.41 million valuation. The stock decreased 1.96% or $0.17 during the last trading session, reaching $8.5. About 208,855 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 11.16% since July 13, 2018 and is uptrending. It has outperformed by 6.73% the S&P500. Some Historical CCXI News: 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 ChemoCentryx 4Q EPS 80c; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/03/2018 – ChemoCentryx 4Q Net $39.7M
Investors sentiment increased to 1.44 in 2019 Q1. Its up 0.51, from 0.93 in 2018Q4. It is positive, as 12 investors sold CCXI shares while 27 reduced holdings. 22 funds opened positions while 34 raised stakes. 33.34 million shares or 22.88% more from 27.13 million shares in 2018Q4 were reported. Qs Invsts Ltd Llc reported 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Charles Schwab Invest Mngmt Inc, a California-based fund reported 49,177 shares. Sectoral Asset reported 17,811 shares stake. California State Teachers Retirement Sys holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 35,245 shares. Alliancebernstein Lp has 46,500 shares for 0% of their portfolio. Clarivest Asset Management invested in 0.01% or 51,400 shares. Proshare Advisors Ltd stated it has 19,606 shares or 0% of all its holdings. Pnc Fincl Services Group Inc invested in 74 shares. Baker Bros LP holds 0.02% or 207,029 shares in its portfolio. Raymond James Associate invested in 0% or 13,874 shares. 310,007 were accumulated by Northern Tru. Swiss Savings Bank has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Art Advsr Ltd Llc holds 23,876 shares. Barclays Public Limited Co holds 13,114 shares or 0% of its portfolio. Rhumbline Advisers holds 0% in ChemoCentryx, Inc. (NASDAQ:CCXI) or 29,704 shares.
Farallon Capital Management Llc decreased Cvs Health Corp (NYSE:CVS) stake by 305,000 shares to 625,000 valued at $33.71M in 2019Q1. It also reduced Novocure Ltd stake by 200,000 shares and now owns 1.05 million shares. Liberty Global Plc (NASDAQ:LBTYK) was reduced too.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 6 analyst reports since February 11, 2019 according to SRatingsIntel. FBR Capital upgraded ChemoCentryx, Inc. (NASDAQ:CCXI) rating on Wednesday, March 27. FBR Capital has “Buy” rating and $22 target. As per Thursday, February 14, the company rating was initiated by Leerink Swann. H.C. Wainwright maintained the shares of CCXI in report on Tuesday, March 12 with “Buy” rating.
Since January 22, 2019, it had 0 insider purchases, and 1 insider sale for $457,747 activity. $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares were sold by KANAYA SUSAN M.
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Finance.Yahoo.com which released: “Hedge Funds Have Never Been More Bullish On ChemoCentryx Inc (CCXI) – Yahoo Finance” on May 09, 2019, also Seekingalpha.com with their article: “InflaRx downdraft engulfs ChemoCentryx, down 28% premarket – Seeking Alpha” published on June 05, 2019, Globenewswire.com published: “ChemoCentryx Reports First Quarter 2019 Financial Results and Recent Highlights – GlobeNewswire” on May 06, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Globenewswire.com and their article: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” published on March 28, 2019 as well as Seekingalpha.com‘s news article titled: “ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” with publication date: March 12, 2019.
ProMIS Neurosciences Inc., a development stage biotech company, discovers and develops precision medicine therapeutics for treatment of neurodegenerative diseases, primarily Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The company has market cap of $38.90 million. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. It currently has negative earnings. The firm applies its thermodynamic, computational discovery platform?ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins.
More important recent ProMIS Neurosciences, Inc. (OTCMKTS:ARFXF) news were published by: Seekingalpha.com which released: “Key events next week – healthcare – Seeking Alpha” on July 12, 2019, also Seekingalpha.com published article titled: “ProMIS Neurosciences completes private placement – Seeking Alpha”, Seekingalpha.com published: “ProMIS Neurosciences identifies antibodies for Alzheimer’s disease – Seeking Alpha” on May 28, 2019. More interesting news about ProMIS Neurosciences, Inc. (OTCMKTS:ARFXF) was released by: Seekingalpha.com and their article: “Biogen and Eisai aducanumab flop pressures ProMIS, down 24% – Seeking Alpha” with publication date: March 21, 2019.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.